Biopharma News

May 25, 2018
By BioPharm International Editors
The gene therapy company is expected to invest $55 million in a new manufacturing facility that will produce therapies for rare neurological genetic diseases.
May 23, 2018
By BioPharm International Editors
The new company will develop proprietary RNA-based therapeutics and will provide broad lentiviral development and manufacturing expertise and support.
May 23, 2018
By BioPharm International Editors
WuXi Biologics will build a biologics manufacturing facility in Singapore that will use both fed-batch and continuous perfusion-based single-use bioreactors.
May 22, 2018
By BioPharm International Editors
The company has leased and purchased facilities in the United States and Europe to expand its cell therapy pipeline.
May 21, 2018
By BioPharm International Editors
The agency approved Amgen and Novartis’ Aimovig (erenumab-aooe), the first FDA-approved preventive treatment for migraine in adults.
May 16, 2018
By BioPharm International Editors
Valerius Biopharma will use Catalent’s GPEx technology to produce cell lines for biosimilar drugs.
May 16, 2018
By BioPharm International Editors
The acquisition is expected to strengthen Novartis’ gene therapy pipeline.
May 16, 2018
By BioPharm International Editors
The agency has approved Retacrit (epoetin alfa-epbx) by Pfizer’s Hospira, which is a biosimilar to Amgen’s anemia drug, Epogen/Procrit (epoetin alfa).
May 15, 2018
By BioPharm International Editors
Eli Lilly will acquire ARMO BioSciences to strengthen Lilly's immuno-oncology program.
May 14, 2018
By BioPharm International Editors
Barriers impede biosimilar market entry into the United States despite the Biologics Price Competition and Innovation Act.
native1_300x100
lorem ipsum